IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
IDEAYA Biosciences (NASDAQ: IDYA) announced the granting of inducement stock options to a new employee. The Compensation Committee approved non-qualified stock options to purchase 31,400 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $24.35 per share, matching IDEAYA's closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.
Positive
- None.
Negative
- None.
News Market Reaction – IDYA
On the day this news was published, IDYA declined 0.33%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302519217.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What stock options did IDEAYA Biosciences (IDYA) grant to its new employee?
What is the vesting schedule for IDEAYA's (IDYA) newly granted stock options?
What is the purpose of IDEAYA's (IDYA) 2023 Inducement Plan?
How long is the term of IDEAYA's (IDYA) newly granted stock options?